Login / Signup

A 12-month, prospective, observational study of ranibizumab in treatment-naïve Taiwanese patients with neovascular age-related macular degeneration: the RACER study.

Wen-Chuan WuJiann-Torng ChenChing-Yao TsaiChien-Liang WuCheng-Kuo ChengYun-Dun ShenArslan TsaiPei-Chang Wu
Published in: BMC ophthalmology (2020)
Treatment with ranibizumab 0.5 mg resulted in significant improvements in visual outcomes among treatment-naïve Taiwanese patients with nAMD. Early treatment and frequent dosing in the real-world setting may be the key to achieving better outcomes.
Keyphrases
  • age related macular degeneration
  • type diabetes
  • metabolic syndrome
  • diabetic retinopathy
  • smoking cessation
  • optical coherence tomography